自拟温润方治疗风寒袭肺型急性咳嗽病的临床观察

目的 观察自拟温润方治疗风寒袭肺型急性咳嗽病的临床疗效。方法 64例风寒袭肺型急性咳嗽病患者,随机分为对照组(31例)和治疗组(33例)。对照组患者给予复方甘草口服溶液治疗,治疗组患者给予温润方治疗。比较两组患者治疗前和治疗3、6 d后的中医症状评分以及临床疗效。结果 治疗3、6 d后,两组患者咳嗽、咯痰、恶风、咽痒、鼻塞、流涕、鼻干、口干咽燥症状评分均低于治疗前,差异均具有统计学意义(P<0.05)。治疗组患者治疗3 d后咳嗽、咽痒、鼻干、口干咽燥症状评分分别为(2.18±0.98)、(1.15±0.81)、(0.60±0.61)、(0.81±0.71)分,均低于对照组的(3.04±1.62)、(1.68±0.96)、(0.96±0.67)、(1.37±0.86)分,差异均具有统计学意义(P<0.05);治疗组患者治疗6 d后咳嗽、咽痒、鼻干、口干咽燥症状评分分别为(0.54±0.51)、(0.42±0.48)、(0.40±0.46)、(0.47±0.51)分,均低于对照组的(1.12±0.76)、(1.11±0.98)、(0.88±0.98)、(1.01±0.92)分,差异均具有统计学意义(P<0.05)。两组患者治疗3、6 d后咯痰、恶风、鼻塞、流涕症状评分比较,差异无统计学意义(P>0.05)。治疗3 d后,治疗组治疗总有效率90.9%高于对照组的71.0%,差异具有统计学意义(P<0.05)。治疗6 d后,治疗组患者治疗总有效率93.9%与对照组的90.3%比较,差异无统计学意义(P>0.05)。结论 在风寒袭肺型急性咳嗽病治疗中,温润方在缓解咳嗽以及部分次症方面明显优于复方甘草口服溶液,起效更快。     

Bipolar disorders: treatment options and patient satisfaction

Functional recovery, the goal of treatment, has long been overlooked in the assessment of effectiveness of pharmacological treatments. However, with the recent shift in paradigm, from syndromal–symptomatic recovery to functional recovery, there appears to be a new interest in the definition and evaluation of functional recovery. Since functional recovery lags symptomatic recovery, sometimes by months or years, the attainment of functional recovery will be determined by both efficacy and long-term compliance. Quetiapine, due to its efficacy in both mania and depression, and effect on cognition may lead to improved functioning in patients with bipolar disorder.     

脉冲微波治疗前列腺炎的临床疗效观察

目的探讨脉冲微波治疗前列腺炎的效果。方法收治前列腺炎病人532例。用南京亿高ECO—100型电脑微波前列腺炎治疗仪,经肛门途径发射脉冲微波,前列腺部位温度控制在41℃~42℃,每次持续45~60min,共七次。以显效、有效为判断疗效标准。结果17~25岁组显效47.93%,有效52.07%,26~45岁组显效52.06%,有效47.94%,两组有效率100%。结论脉冲微波经肛门途径治疗前列腺炎效果明显,有推广价值。     

MEBO治疗口腔、咽、食管烧伤临床观察

目的:探讨口腔、咽、食管烧伤的治疗方法。方法:对2000年3月-2005年12月,采取口服湿润烧伤膏(MEBO)治疗的25例患者进行回顾性资料总结。结果:25例病人均治愈,无创面感染、食管狭窄、腹泻等并发症。结论:MEBO对口腔、咽、食管等上消化道部位黏膜烧伤疗效确切,方法简单易行。     

痛结宁胶囊治疗乳腺增生病的临床疗效观察

目的 :评价痛结宁胶囊治疗乳腺增生病的临床疗效。方法 :30 0例乳腺增生病病人随机分成两组。治疗组 2 4 0例 ,口服痛结宁胶囊 ,每次 3粒 ,1日 3次。对照组 60例 ,口服维生素 E,1 0 0 mg,1日 1次。疗程 3个月。用 Ridit检验分析疗效。结果 :治疗组治愈率 2 1 .67% ,总有效率 88.75 % ;对照组治愈率 1 1 .67% ,总有效率 46.67% ,治疗组疗效明显优于对照组 ( P<0 .0 1 )。结论 :痛结宁治疗乳腺增生病有较好的疗效 ,病程越短 ,疗效越好 ,延长治疗时间可以提高治疗效果     

仙草消毒液杀灭微生物效果与毒性的试验观察

仙草消毒液为含 3 0 %乙醇的植物消毒剂 ,其中包括五味子、细辛、丁香等成分 ,p H6.0 1。为了解其杀灭微生物效果及其毒性 ,进行了载体定量杀菌试验及毒性试验。结果 ,1∶ 1的水稀释液对金黄色葡萄球菌作用2分钟 ,1∶ 2的稀释液对金黄色葡萄球菌作用 8分钟 ,以其原液对白色念珠菌作用 2 min,平均杀灭率均大于99.90 %。小牛血清对其杀灭效果有影响 ,原液经 5 4℃存放 14天 ,杀菌效果无明显变化。以其原液对雌、雄小鼠经口 LD50 >5 0 0 0 mg/Kg,对大耳白兔一次眼、皮肤刺激试验平均积分指数为 0 ,微核试验阴性 ,蓄积毒性试验为弱蓄积毒性     

影响利培酮治疗精神分裂症疗效因素分析

目的　探讨影响利培酮对精神分裂症疗效的关键因素。方法　对 57例单用利培酮治疗的精神分裂症患者 ,采用一系列标准评定工具对 39个临床指标进行定量或半定量评估。并作Logistic回归分析。将治疗后简明精神病评定量表 (BPRS)减分率≥ 30 %者确定为“有效”。结果　单因素分析显示 :服药依从性 ,MMPI中Sc、Si、D因子 ,治疗前BPRS 2和BPRS 4因子 ,TESS 3因子 ,家族史 ,起病形式 ,意识模糊 ,住院时间与利培酮疗效有关 ;经多因素分析有服药依从性 ,MMPI(Sc) ,BPRS 2 ,家族史 ,意识模糊等 5个指标选入回归方程。结论　影响利培酮对精神分裂症疗效的关键因素依次为服药依从性 ,MMPI中精神分裂因子 ,阴性症状 ,家族史及意识模糊     

Long‐term efficacy of biologics in the treatment of psoriasis: what do we really know?

Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab, * etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab).     

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

Background  Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses.
Objectives  To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods  A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results  A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions  In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care.